Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of Belimumab in Adults With ILD Associated With SSc and Other CTD
NCT06716606Phase 3Recruiting
- Sponsor
- GSK
- Start
- Dec 2024
- Primary completion
- Sep 2030
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 3, open-label, single-arm trial of belimumab in interstitial lung disease (ILD), sponsored by GSK. Primary endpoint: Adverse Events at 5 years. Started Dec 2024; status: recruiting.
02
Drugs
belimumab
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT06716606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06716606.